Purdue Pharma LP
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1892-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.purduepharma.com
Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain
- Conditions
- Other Acute Postoperative PainProlonged Endotracheal Intubation
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Purdue Pharma LP
- Registration Number
- NCT01324544
Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 41
- Registration Number
- NCT01324570
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Willis-Knighton Physician Network, Shreveport, Louisiana, United States
🇺🇸Howard University Hospital, Washington, D.C., District of Columbia, United States
Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole
- Conditions
- Healthy
- Interventions
- Drug: Placebo to match ketoconazole tablet
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 20
- Registration Number
- NCT01259115
- Locations
- 🇺🇸
Clinical Research Center, New Orleans, Louisiana, United States
Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 70
- Registration Number
- NCT01259102
- Locations
- 🇺🇸
The Ohio State University Department of Pharmacology, Columbus, Ohio, United States
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 155
- Registration Number
- NCT01192295
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Research Facility, The Woodlands, Texas, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients
- Conditions
- Opioid Analgesia
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 30
- Registration Number
- NCT01160614
- Locations
- 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
🇺🇸Research Facility, Miami, Florida, United States
🇺🇸LS Packard Children's Hospital, Palo Alto, California, United States
Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
- Conditions
- Chronic Nonmalignant Pain
- Interventions
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 189
- Registration Number
- NCT01151098
- Locations
- 🇺🇸
University Clinical Research Deland, Deland, Florida, United States
🇺🇸Pain Management & Rehabilitation, Terre Haute, Indiana, United States
🇺🇸Arizona Research Center Inc., Phoenix, Arizona, United States
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Matching placebo transdermal patch
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 132
- Registration Number
- NCT01148537
- Locations
- 🇺🇸
PPD Development, LP, Clinics, Austin, Texas, United States
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 290
- Registration Number
- NCT01141283
- Locations
- 🇺🇸
Arthrocare, Arthritis Care and Research, Phoenix, Arizona, United States
🇺🇸Great Lakes Family Care, Cadillac, Michigan, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 196
- Registration Number
- NCT01135524
- Locations
- 🇺🇸
HealthCare Research LLC, St. Louis, Missouri, United States
🇺🇸Louisville Endocrinology PSC, Louisville, Kentucky, United States
🇺🇸Alabama Neurology and Pain Medicine, Alabaster, Alabama, United States